NXL Stock Overview
A medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Nexalin Technology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.70 |
| 52 Week High | US$3.40 |
| 52 Week Low | US$0.25 |
| Beta | 0 |
| 1 Month Change | -58.58% |
| 3 Month Change | 112.12% |
| 1 Year Change | -21.35% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -68.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| NXL | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -30.7% | -1.2% | -1.2% |
| 1Y | -21.3% | 1.8% | 21.5% |
Return vs Industry: NXL underperformed the US Medical Equipment industry which returned 1.8% over the past year.
Return vs Market: NXL underperformed the US Market which returned 21.5% over the past year.
Price Volatility
| NXL volatility | |
|---|---|
| NXL Average Weekly Movement | 38.9% |
| Medical Equipment Industry Average Movement | 7.8% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: NXL's share price has been volatile over the past 3 months.
Volatility Over Time: NXL's weekly volatility has increased from 25% to 39% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 6 | Mark White | www.nexalin.com |
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer’s disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues.
Nexalin Technology, Inc. Fundamentals Summary
| NXL fundamental statistics | |
|---|---|
| Market cap | US$5.39m |
| Earnings (TTM) | -US$4.94m |
| Revenue (TTM) | US$158.86k |
32.8x
P/S Ratio-1.1x
P/E RatioIs NXL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NXL income statement (TTM) | |
|---|---|
| Revenue | US$158.86k |
| Cost of Revenue | US$27.73k |
| Gross Profit | US$131.13k |
| Other Expenses | US$5.07m |
| Earnings | -US$4.94m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.66 |
| Gross Margin | 82.54% |
| Net Profit Margin | -3,110.59% |
| Debt/Equity Ratio | 0% |
How did NXL perform over the long term?
See historical performance and comparison